



A Beneficência
Portuguesa
de São Paulo



DR. JULIAN GILLMORE

Dr Gillmore has an international reputation in the field of amyloidosis, consolidating the work he performed in this area during his MD and PhD studies. He has published extensively on amyloidosis and continues to do so.

He developed a network of haematologists across the UK who have an interest in treating patients with the commonest form of amyloidosis, AL type, which he harnessed to undertake the first randomized controlled trial of treatment in this most serious disease. He was involved with the foundation of the UK patient support group and is chair and principal author of the British Guidelines on management of AL amyloidosis.

He highlighted for the first time in a systematic fashion, the relationship between the abundance of amyloid fibril precursor proteins, the course of amyloid deposits and clinical outcome in a number of different forms of amyloidosis. His widely cited seminal 2001 paper published in the Lancet had a major impact on management of AA amyloidosis and amyloidosis generally.

In 2016, he established and validated the non-biopsy diagnostic criteria for cardiac ATTR amyloidosis which have been adopted worldwide and resulted in a huge increase in diagnoses of this form of cardiomyopathy. He has been involved in all the major 'gene silencing' trials in ATTR amyloidosis and was lead author of the first trial of in vivo gene editing in humans.